Roche announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society.
The award, which celebrates the importance of pharmacology in the development of new medicines, was presented to the vismodegib team because of the detailed pharmacokinetic/pharmacodynamic analysis that was completed during the drug development process. Vismodegib is currently approved in the US and Mexico for the teatment of individuals with an advanced form of the common skin cancer basal cell carcinoma.
For further information visit the following link.
Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello. We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support.
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361